VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in ...

Saber CEO Matthew Karch, whose company used to be part of Embracer alongside Volition, explains what happened to the defunct ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow ...

Which is certainly a look.

VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025, VolitionRx (NYSE:VNRX) made a significant milestone announcement that, ...

Saints Row studio Volition shut down in 2023 after 30 years, leading many to wonder about the future of the open-world crime ...

"The Nu.Q® Cancer test could support physicians with clinical decision-making following LDCT by identifying the patients at highest risk and whose nodules are more likely to be cancerous, while ...

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 ...

When the fishing vessel Volition broke up on the night of 27 February after running aground very early that day, Bermagui ...

VolitionRx (VNRX) announced the expansion of its Nu.Q Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan, to include ...